Key result
Routine blood pressure surveillance during immune checkpoint inhibitor therapy identified hypertensive mean readings in 7.5% of patients, half of whom had no known history of hypertension.
Why the study?
ICIs increase ASCVD risk, but routine day oncology BP measurements are often not assessed temporally to screen and monitor hypertension.
Is it feasible to use serial blood pressure measurements from routine oncology visits to diagnose and monitor hypertension in cancer patients receiving immune checkpoint inhibitors?
Observational (n=366)
No
Is it feasible to use serial blood pressure measurements from routine oncology visits to diagnose and monitor hypertension in cancer patients receiving immune checkpoint inhibitors?
Serial blood pressure measurements during routine oncology visits may offer a feasible method to screen and monitor hypertension in cancer patients receiving immune checkpoint inhibitors.
Serial BP monitoring during ICI visits is feasible; leaves open whether it improves hypertension control or ASCVD outcomes in cancer survivors.
Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2023) conducted an observational in Cancer patients treated with immune checkpoint inhibitors (n=366). Routine blood pressure surveillance during immune checkpoint inhibitor therapy was evaluated on Number of patients with hypertensive readings (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg). Routine blood pressure surveillance during immune checkpoint inhibitor therapy identified hypertensive mean readings in 7.5% of patients, half of whom had no known history of hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: